Eyenovia Inc (EYEN) Receives Average Rating of “Strong Buy” from Analysts
Shares of Eyenovia Inc (NASDAQ:EYEN) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Analysts have set a one year consensus price objective of $27.50 for the company and are anticipating that the company will post ($0.45) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Eyenovia an industry rank of 98 out of 255 based on the ratings given to its competitors.
Separately, Zacks Investment Research upgraded shares of Eyenovia from a “hold” rating to a “buy” rating and set a $6.25 price objective for the company in a report on Friday, August 17th.
Hedge funds have recently added to or reduced their stakes in the business. Fairpointe Capital LLC bought a new stake in Eyenovia during the second quarter valued at about $313,000. Sabby Management LLC bought a new stake in Eyenovia during the first quarter valued at about $908,000. Highbridge Capital Management LLC bought a new stake in Eyenovia during the first quarter valued at about $1,373,000. Millennium Management LLC bought a new stake in Eyenovia during the first quarter valued at about $2,525,000. Finally, Uniplan Investment Counsel Inc. bought a new stake in Eyenovia during the first quarter valued at about $3,248,000. Institutional investors own 12.28% of the company’s stock.
Shares of NASDAQ:EYEN opened at $4.54 on Tuesday. The firm has a market capitalization of $47.99 million and a P/E ratio of -2.07. Eyenovia has a 1 year low of $4.70 and a 1 year high of $10.74.
Eyenovia (NASDAQ:EYEN) last issued its quarterly earnings data on Tuesday, August 14th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.09. analysts anticipate that Eyenovia will post -1.73 EPS for the current fiscal year.
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
Read More: What is the NASDAQ?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.